Table 1.
Adherence to and persistence with second-generation oral antipsychotic therapy among US Medicaid-enrolled patients with schizophrenia
| Characteristics | All patients |
|---|---|
| Total sample size, n (%) | 3714 (100.00) |
| Adherencea | |
| MPR, mean (SD)b | 0.66 (0.30) |
| MPR distribution (0.80 threshold), n (%) | |
| 0–0.19 | 415 (11.17) |
| 0.20–0.39 | 491 (13.22) |
| 0.40–0.59 | 565 (15.21) |
| 0.60–0.79 | 570 (15.35) |
| 0.80–1.00 | 1673 (45.05) |
| Non-adherent total (MPR < 0.80), n (%) | 2041 (54.95) |
| Adherent total (MPR ≥ 0.80), n (%) | 1673 (45.05) |
| Persistence, n (%)c | |
| Therapy interruption (refill gap > 60 days with subsequent re-initiation) | 848 (22.83) |
| Therapy discontinuation (without subsequent SGOA re-initiation) | 1010 (27.19) |
| Continuous SGOA use | 1856 (49.97) |
| Non-persistent total (had therapy interruption or discontinuation) | 1858 (50.03) |
| Persistent total (had continuous SGOA use) | 1856 (49.97) |
a
Adherence measured during the 12-month postindex period after the first evidence of SGOA use.
b
MPR, total days of SGOA therapy ÷ (365 – days hospitalized).
c
Persistence measured during the 12-month postindex period after the first evidence of SGOA use. Persistence is defined as continuous use of SGOAs (i.e. no refill gap or refill gap of ≤60 days for SGOA medication). Non-persistence is defined as therapy interruption (i.e. refill gap for the SGOA medication > 60 days) or SGOA discontinuation.
MPR, medication possession ratio; SD, standard deviation; SGOA, second-generation oral antipsychotic.